September 17, 2020 | Blog
Pharmaceutical products can both exceed and fall short of blockbuster sales expectations by considerable margins which can be a result of a number of reasons. Some of these include the value of first-to-market dynamics, supporting real-world evidence to gain a competitive edge, and continual investment in trials for follow-on indications to improve life cycle management.
September 8, 2020 | Blog
Blockbuster drugs can generate billions of dollars for pharmaceutical manufacturers, but what can be learned from the investment strategies that GILEAD and VERTEX pursued from the revenue that they generated from SOVALDI and ORKAMBI respectively?
August 25, 2020 | Blog
COVID-19 has presented an abundance of short-term implications and challenges for biopharma companies; however, it is useful to understand and prepare for the longer-term impacts as the acute disruptions to regulatory processes and healthcare delivery begin to subside. To proactively prepare for a post-COVID-19 world, biopharma leaders should develop strategies to integrate technology across the value chain and increase focus on patient centricity in terms of process flows and treatment administration.
August 5, 2020 | Blog
Since its inception over 30 years ago, the 340B drug pricing program policy has evolved allowing for unprecedented expansion and influence. With this it has also become highly contested, especially in recent years as more legislation has been put forward to close 340B loopholes.
July 14, 2020 | Blog
CBPartners’ in collaboration with Eric Bernath, explores the current USA access landscape, processes and pitfalls for companion digital therapeutics (DTx), as well as how the space is likely to evolve in the future, and lays out some best practices as suggested by USA payers to maximize chances of reimbursement.